<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-11T06:12:16Z</responseDate>
  <request identifier="oai:figshare.com:article/34040160" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34040160</identifier>
        <datestamp>2026-10-01T05:49:43Z</datestamp>
        <setSpec>category_696</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_10_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Image 5_Single-cell mass cytometry cartography highlights systemic lupus erythematosus and Sjögren’s disease immune differences.jpeg</dc:title>
          <dc:creator>Franziska Szelinski (6261920)</dc:creator>
          <dc:creator>Ana-Luisa Stefanski (7420553)</dc:creator>
          <dc:creator>Annika Wiedemann (6261908)</dc:creator>
          <dc:creator>Hector Rincon-Arevalo (7420556)</dc:creator>
          <dc:creator>Eva Schrezenmeier (6261917)</dc:creator>
          <dc:creator>Tobias Alexander (503838)</dc:creator>
          <dc:creator>Van Duc Dang (12372187)</dc:creator>
          <dc:creator>Andreas Frei (2037805)</dc:creator>
          <dc:creator>Andreia C. Lino (6261923)</dc:creator>
          <dc:creator>Thomas Dörner (11519)</dc:creator>
          <dc:subject>Genetic Immunology</dc:subject>
          <dc:subject>pSjD</dc:subject>
          <dc:subject>pSS</dc:subject>
          <dc:subject>SLE</dc:subject>
          <dc:subject>B cells</dc:subject>
          <dc:subject>T cells</dc:subject>
          <dc:subject>innate cells</dc:subject>
          <dc:subject>mass cytometry</dc:subject>
          <dc:description>Objectives&lt;p&gt;Autoimmune diseases such as primary Sjögren’s disease (pSjD) and systemic lupus erythematosus (SLE) share clinical and serological features, including type I interferon signatures, autoantibody formation, and chronic inflammation, but the underlying immunopathology is not the same. To support the development of targeted therapies, we aimed to systematically characterize disease-specific alterations in peripheral immune cell subsets of pSjD and SLE compared to healthy donors (HD).&lt;/p&gt;Methods&lt;p&gt;We analyzed peripheral blood mononuclear cells from 15 HD, 12 pSjD and 21 SLE patients by mass cytometry. We manually pre-gated viable CD19&lt;sup&gt;+&lt;/sup&gt; B cells, CD3&lt;sup&gt;+&lt;/sup&gt; T cells, and innate immune populations before performing high-dimensional, consensus clustering. We compared relative subset frequencies and marker expression, including costimulatory and inhibitory receptors, between the three cohorts.&lt;/p&gt;Results&lt;p&gt;In the B cell compartment, we identified 13 clusters. SLE patients showed an relative expansion of plasmablasts and two double-negative (IgD&lt;sup&gt;−&lt;/sup&gt;CD27&lt;sup&gt;−&lt;/sup&gt;) B cell clusters, one CD21&lt;sup&gt;−&lt;/sup&gt; and one CD19&lt;sup&gt;low&lt;/sup&gt; with high IgA. Both had an activated phenotype with elevated CD38, CD86, and Ki-67. In SLE, the costimulatory molecules CD86 and CD226 were upregulated on memory and DN B cells. By contrast, B cell changes in pSjD were more modest. We found 12 T cells clusters. Both diseases had increased CD4&lt;sup&gt;+&lt;/sup&gt; PD-1&lt;sup&gt;+&lt;/sup&gt; ICOS&lt;sup&gt;+&lt;/sup&gt; circulating T follicular helper-like cells, and pSjD showed expansion of CD8&lt;sup&gt;+&lt;/sup&gt; effector memory (Tem) and terminally differentiated (Temra) T cell subsets. Relative innate cell frequencies did not differ substantially between groups, however, intermediate CD226&lt;sup&gt;hi&lt;/sup&gt; monocytes were reduced in SLE but showed higher activation marker expression (CD86, HLA-DR). Network correlation analysis revealed higher immune‐cell connectivity in SLE compared to pSjD.&lt;/p&gt;Conclusion&lt;p&gt;SLE is characterized by B cell activation, plasmablast expansion, and costimulatory upregulation, while pSjD is mainly defined by alterations in the CD8&lt;sup&gt;+&lt;/sup&gt; T cell compartment. These disease‐specific immunologic signatures highlight distinct patterns in SLE and pSjD and generate hypotheses for future studies investigating targeted therapeutic approaches.&lt;/p&gt;</dc:description>
          <dc:date>2026-10-01T05:49:43Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.3389/fimmu.2026.1834700.s006</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/Image_5_Single-cell_mass_cytometry_cartography_highlights_systemic_lupus_erythematosus_and_Sj_gren_s_disease_immune_differences_jpeg/34040160</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
